Stake logo



About IDYA

IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The Company is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.

Buy US stocks in Australia starting with IDYA. Open an account and start investing today!

Market Capitalisation


Price-earnings ratio


Dividend yield




High today


Low today


Open price


52-week high


52-week low



One share of IDEAYA BIOSCIENCES INC is valued at $17.29.

The ticker symbol for IDEAYA BIOSCIENCES INC is IDYA.

To buy IDYA stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in IDYA

As of 07/02/2023 IDEAYA BIOSCIENCES INC has a market cap of $831M.

The IDEAYA BIOSCIENCES INC 52-week high stock price is $19.14.

The IDEAYA BIOSCIENCES INC 52-week low stock price is $8.14.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.